Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Neem’s Hill

2.00 SEK0.00 %20.11, 17.25
Less than 1K followers

NEEMS B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
0.00 %
-20.63 %
-35.28 %
-45.65 %
-60.16 %
-45.95 %
-14.69 %
-89.02 %
-94.69 %

Neem’s Hill is a Swedish company that develops and markets medical technology based on electrochemotherapy for the treatment of cancer. The company offers systems and solutions to clinics in oncology and veterinary medicine and has operations in international markets, including India and Southeast Asia. The company was founded in 2015 and is headquartered in Lund, Sweden.

Read more
Market cap
52.43M SEK
Turnover
54.26 SEK
Revenue
12.29M
EBIT %
-52.61 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
23.2
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release03.11.2026, 11.58

Neem's Hill AB: Neem's Hill surpasses 5,000 Animal Care treatments sold as recurring kit sales grow

Neem’s Hill
Press release28.10.2026, 11.45

Redeye: Neem’s Hill (Q3 Review): Underlying progress points to sales growth

Neem’s Hill
Regulatory press release27.10.2026, 08.30

Neem's Hill AB (publ) publishes Interim report Q3 2026

Neem’s Hill

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release23.09.2026, 11.12

Redeye: Neem’s Hill: Positive update ahead of Q3 report

Neem’s Hill
Press release22.09.2026, 13.00

Neem's Hill - Building the Next Chapter

Neem’s Hill
Regulatory press release11.08.2026, 08.30

Neem's Hill AB (publ) publishes Interim report Q2 2026

Neem’s Hill
Regulatory press release13.07.2026, 08.45

Scandinavian ChemoTech AB changes name to Neem's Hill AB

Neem’s Hill
Regulatory press release01.07.2026, 12.46

ChemoTech's TSE Reports 97% Complete Remission and Stronger Than Expected Clinical Results in Equine

Neem’s Hill
Press release01.07.2026, 08.30

ChemoTech: Clinical Publication on TSE Therapy for the Treatment of Equine Sarcoids to Be Presented During ECVS

Neem’s Hill
Press release25.06.2026, 09.47

ChemoTech Enters Strategic Partnership with the University of Copenhagen's Veterinary Hospitals

Neem’s Hill
Regulatory press release02.06.2026, 17.51

Corr. of press release: ChemoTech secures 6 MSEK Growth Loan from a Swedish Financial Institution

Neem’s Hill
Regulatory press release02.06.2026, 16.16

Scandinavian ChemoTech secures SEK 6 million Growth Loan from a larger Swedish Financial Institution

Neem’s Hill
Regulatory press release19.05.2026, 15.13

ChemoTech announces outcome of the directed issue

Neem’s Hill
Regulatory press release28.04.2026, 08.30

Scandinavian ChemoTech AB (publ) publishes Interim report Q1 2026

Neem’s Hill
Press release07.04.2026, 14.40

ChemoTech's Proposed Strategic Changes Accepted by Nasdaq First North

Neem’s Hill
Press release02.04.2026, 08.45

(RETRANS) Scandinavian ChemoTech Starts 2026 Strong with Best First Quarter in Company History

Neem’s Hill
Regulatory press release01.04.2026, 16.50

Scandinavian ChemoTech Starts 2026 Strong with Best First Quarter in Company History

Neem’s Hill
Regulatory press release31.03.2026, 08.15

ChemoTech proposes expanded business activities, name change & received proposal on directed issue

Neem’s Hill
Regulatory press release17.03.2026, 13.37

ChemoTech's subsidiary Scandinavian Meditech Achieves Full CDSCO MD-15 Import License in India

Neem’s Hill
Press release19.02.2026, 09.43

Redeye: Scandinavian ChemoTech (Q4 Review): Seasonal softness, intact growth case

Neem’s Hill